Compound Detail
CHEMBL753
PHENOXYBENZAMINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL753 |
| Name | PHENOXYBENZAMINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | QZVCTJOXCFMACW-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
6
Targets
7
Activities
2
Assay Types
1
PK Parameters
20
Publications
5
Known Names
4
Indications
Molecular Properties
303.8
MW (Da)
4.19
ALogP
2
HBA
0
HBD
12.5
PSA (Ų)
0.68
QED
0
Ro5 Violations
8
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1953 |
| Availability | Prescription |
| Chirality | Racemic |
Indications
Cardiovascular Diseases Paraganglioma Pheochromocytoma Hernias, Diaphragmatic, Congenital
ATC Classification
C04AX02
phenoxybenzamine
Level 1: CARDIOVASCULAR SYSTEM
Level 2: PERIPHERAL VASODILATORS
Activity Summary
IC50 5 meas. best 5.57
Ki 2 meas. best 8.74
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Adrenergic receptor alpha-1 CHEMBL1907610 | Ki | 8.74 | 8.74 | 1.8 | 1 |
| Dopamine receptor CHEMBL2093868 | Ki | 6.92 | 6.92 | 120.0 | 1 |
| Solute carrier family 22 member 1 CHEMBL5685 | IC50 | 5.57 | 5.195 | 2720.0 | 2 |
| Solute carrier family 22 member 2 CHEMBL1743122 | IC50 | 5.31 | 5.31 | 4900.0 | 1 |
| Solute carrier family 22 member 3 CHEMBL2073673 | IC50 | 5.21 | 5.21 | 6130.0 | 1 |
| Sodium channel alpha subunits; brain (Types I, II, III) CHEMBL2096682 | IC50 | 4.35 | 4.35 | 45000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| Cmax | 197.0 | nM | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 31477 | 10.1021/jm00209a007 | Unchecked | 5 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 4 |
| 20014752 | 10.1021/tx900326k | Hepatotoxicity | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 2 |
| 24799086 | 10.1002/hep.27206 | Homo sapiens | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Estrogen receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Glucocorticoid receptor | 2 |
| 22931300 | 10.1021/tx300075j | Cytochrome P450 3A4 | 2 |
| 22931300 | 10.1021/tx300075j | Liver microsomes | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
| 2579237 | 10.1021/jm00381a019 | Sodium channel alpha subunits; brain (Types I, II, III) | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| 18788725 | 10.1021/jm8003152 | Solute carrier family 22 member 1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Peroxisome proliferator-activated receptor gamma | 2 |
Data from ChEMBL 36 via Core Engine